Open AccessSafety and efficacy of gefapixant, a novel drug for the treatment of chronic cough: A systematic review and meta-analysis of randomized controlled trials
Author(s) -
Ahmed AbuZaid,
Aseel Khalid Aljaili,
Amnah Althaqib,
Fatima Adem,
Doaa Ali Alhalal,
Amena Faiq Almubarak,
Saud Musaab Aldughaither,
Sarah A. Alghabban,
Ghaidaa A. Alfaraj,
Ahmed Taher Masoud,
Nujud Abdullah Alsuhaibani
Publication year - 2021
Publication title -
annals of thoracic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.639
H-Index - 33
eISSN - 1817-1737
pISSN - 1998-3557
DOI - 10.4103/atm.atm_417_20
Subject(s) - medicine , confidence interval , placebo , meta analysis , chronic cough , adverse effect , incidence (geometry) , randomized controlled trial , relative risk , visual analogue scale , anesthesia , alternative medicine , asthma , physics , pathology , optics
We conducted this systematic review and meta-analysis to investigate the efficacy and safety of gefapixant, a novel P2X3 receptor antagonist, in patients with chronic cough.